Prevalence and clinical impact of latent tuberculosis infection in patients with inflammatory bowel disease in Japan: a retrospective multicenter study by the IBD-Quality team - PubMed
14 hours ago
- #Inflammatory Bowel Disease
- #Immunosuppressive Therapy
- #Latent Tuberculosis Infection
- The study aimed to determine the prevalence of latent tuberculosis infection (LTBI) in Japanese patients with inflammatory bowel disease (IBD) and evaluate its impact on therapeutic management.
- A retrospective multicenter study was conducted involving 4,257 IBD patients (1,646 with Crohn's disease and 2,611 with ulcerative colitis) from 10 Japanese institutions between 2010 and 2020.
- The prevalence of LTBI among the patients was found to be 1.62%, with 69 patients testing positive.
- Ustekinumab and vedolizumab were used more frequently in the LTBI group compared to the non-LTBI group.
- 82.6% of LTBI-positive patients received preventive treatment, while 17.4% were followed without treatment; only ustekinumab and vedolizumab were chosen as advanced therapies in these cases.
- Two patients developed active tuberculosis despite preventive treatment while on immunosuppressive agents, indicating the need for careful monitoring.
- The study concludes that LTBI status and preventive treatment influence the selection of advanced therapies for IBD, and active tuberculosis, though rare, can still occur post-treatment.